| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
67,050,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s clinical stage product candidates include: ORIC-533, an orally bioavailable small molecule inhibitor of CD73 which playing a role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of polycomb repressive complex 2 via the embryonic ectoderm development subunit.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,000 |
105,103 |
145,103 |
165,636 |
| Total Sell Value |
$648,380 |
$1,353,228 |
$1,674,000 |
$1,738,870 |
| Total People Sold |
1 |
3 |
3 |
3 |
| Total Sell Transactions |
1 |
6 |
10 |
16 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-29 |
4 |
AS |
$23.31 |
$1,761,187 |
I/I |
(75,555) |
2,240,440 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-29 |
4 |
AS |
$23.31 |
$1,761,187 |
I/I |
(75,555) |
2,240,440 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-26 |
4 |
AS |
$23.88 |
$664,246 |
I/I |
(27,816) |
2,315,995 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-26 |
4 |
AS |
$23.88 |
$664,246 |
I/I |
(27,816) |
2,315,995 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-25 |
4 |
AS |
$24.70 |
$1,272,618 |
I/I |
(51,523) |
2,343,811 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-25 |
4 |
AS |
$24.70 |
$1,272,618 |
I/I |
(51,523) |
2,343,811 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-24 |
4 |
AS |
$24.80 |
$817,383 |
I/I |
(32,959) |
2,395,334 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-24 |
4 |
AS |
$24.80 |
$817,383 |
I/I |
(32,959) |
2,395,334 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-23 |
4 |
AS |
$24.32 |
$97,085 |
I/I |
(3,992) |
2,428,293 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-23 |
4 |
AS |
$24.32 |
$97,085 |
I/I |
(3,992) |
2,428,293 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-22 |
4 |
AS |
$26.47 |
$203,104 |
I/I |
(7,673) |
2,432,285 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-22 |
4 |
AS |
$26.47 |
$203,104 |
I/I |
(7,673) |
2,432,285 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-19 |
4 |
AS |
$26.47 |
$563,149 |
I/I |
(21,275) |
2,439,958 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-19 |
4 |
AS |
$26.47 |
$563,149 |
I/I |
(21,275) |
2,439,958 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-18 |
4 |
AS |
$28.03 |
$169,834 |
I/I |
(6,059) |
2,461,233 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-18 |
4 |
AS |
$28.03 |
$169,834 |
I/I |
(6,059) |
2,461,233 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-17 |
4 |
AS |
$28.43 |
$534,200 |
I/I |
(18,790) |
2,467,292 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-17 |
4 |
AS |
$28.43 |
$534,200 |
I/I |
(18,790) |
2,467,292 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-16 |
4 |
AS |
$27.72 |
$1,146,305 |
I/I |
(41,353) |
2,486,082 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-16 |
4 |
AS |
$27.72 |
$1,146,305 |
I/I |
(41,353) |
2,486,082 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-15 |
4 |
AS |
$29.14 |
$2,599,579 |
I/I |
(89,210) |
2,527,435 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-15 |
4 |
AS |
$29.14 |
$2,599,579 |
I/I |
(89,210) |
2,527,435 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-12 |
4 |
AS |
$30.29 |
$2,741,881 |
I/I |
(90,521) |
2,616,645 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-03-12 |
4 |
AS |
$30.29 |
$2,741,881 |
I/I |
(90,521) |
2,616,645 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2021-03-11 |
4 |
AS |
$33.04 |
$1,934,525 |
I/I |
(58,551) |
2,707,166 |
|
- |
|
118 Records found
|
|
Page 4 of 5 |
|
|
